ACDIS Updated CCDS-O Exam Questions and Answers by jiya

The most compliant query is the one that is clinically supported, non-leading, and focused on clarifying documentation for correct reporting and medical necessity—without directing the provider to “add” diagnoses or document conditions for payment purposes. Option A presents relevant clinical context (no GI symptoms; family history) and asks the provider to clarify whether the planned colonoscopy is screening or diagnostic, which is a legitimate documentation clarification affecting correct code selection and coverage rules. It does not imply a desired answer and does not instruct the provider to document additional diagnoses. Option B is problematic because it instructs the provider to “document these conditions” if treated, which can be perceived as prompting and is not tied to encounter-specific indicators. Option C is based primarily on historical information and asks a yes/no about remission, which can be leading and may not reflect current-visit evaluation. Option D effectively asks the provider to add a diagnosis based on nursing documentation, which risks leading language and requires provider confirmation and assessment. Therefore, A is most compliant.

The record contains conflicting documentation: the problem list includes both “type 2 diabetes without complications” and diabetes with complications (erectile dysfunction association), while the most recent clinic note indicates the provider addressed “DM2 with autonomic neuropathy,” which is clearly a diabetic complication. In outpatient CDI, the first priority is to resolve internal inconsistency so coding accurately reflects the patient’s current clinical status and what was evaluated/managed at the encounter. A query should therefore focus on whether the patient’s diabetes iswith complications(and which complications are active/being addressed) versus trulywithout complications, because “without complications” is generally not appropriate when neuropathy/other manifestations are present and being managed. CDI staff also should not unilaterally remove items from the provider-maintained problem list, and asking the patient is not a reliable documentation/coding source for establishing diagnoses. Once the provider clarifies diabetes complication status, a follow-up clarification can address specific linkages (e.g., erectile dysfunction due to diabetes) if needed for correct code assignment

This question applies the outpatient risk adjustment “reserve” concept: predicted cost is estimated by multiplying the member’s risk factor contribution by a baseline per-member-per-month (PMPM) amount, then annualizing. The morbid obesity HCC factor is 0.186, and PMPM is $800. First compute the monthly cost impact: $800 × 0.186 = $148.80 per month per patient. Convert to yearly: $148.80 × 12 = $1,785.60 per patient per year. The year-over-year increase in patients with morbid obesity documentation is 11,000 − 10,000 = 1,000 additional patients. Multiply the annual per-patient impact by the additional patient count: $1,785.60 × 1,000 = $1,785,600. Outpatient CDI programs emphasize that improving documentation specificity (when clinically supported) can change whether an HCC is captured, which can affect RAF-based projections and resource planning. However, documentation must still be accurate, supported, and reflect conditions assessed/managed during the encounter.

In outpatient CDI chart review, a key skill is recognizing when medications and treatment plans suggest a specific diabetic complication that is not explicitly documented. Gabapentin is commonly prescribed for neuropathic pain, and in a diabetic patient it is frequently used to treatdiabetic peripheral neuropathysymptoms (burning, tingling, numbness, shooting pain). ACDIS outpatient CDI guidance supports querying when there are strong clinical indicators that a more specific, clinically relevant diagnosis may be present and is being treated at the encounter, because diabetes codes require complication specificity when supported (e.g., “diabetes with neuropathy” rather than unspecified diabetes). The elevated glucose and A1C confirm ongoing diabetes management but do not, by themselves, indicate CKD, macular degeneration, or ketoacidosis. Ketoacidosis would require documentation of acute metabolic decompensation and supporting clinical/lab findings, which are not provided here. Therefore, the most appropriate clarification is whether the patient has diabetic peripheral neuropathy (and whether it is painful neuropathy) being managed with gabapentin, so the provider can document the condition clearly and accurately.